Furthermore, SHP2 allosteric inhibition sensitizes immunotherapy-resistant CRC, particularly in tumors characterized by high SIRPα and SHP2 expression with low NEDD8 levels. The gene discussed is PTPN11; the disease is colorectal carcinoma.